Technical Analysis for AKCA - Akcea Therapeutics, Inc.

Grade Last Price % Change Price Change
grade B 30.25 3.74% 1.09
AKCA closed up 3.74 percent on Thursday, July 19, 2018, on 44 percent of normal volume. Due to the stock's strong uptrend, it may remain overbought for a while. So, if you're looking for a reason to sell, don't put too much weight on it being overbought.

Trend Table & Recent Alerts
ADX Long-Term Intermediate-Term Short-Term
Strong Up Up Up
See historical AKCA trend table...

Date Alert Name Type % Chg
Jul 19 Upper Bollinger Band Walk Strength 0.00%
Jul 19 Multiple of Ten Bullish Other 0.00%
Jul 19 Above Upper BB Strength 0.00%
Jul 19 Overbought Stochastic Strength 0.00%
Jul 19 Upper Bollinger Band Touch Strength 0.00%
Jul 18 New Uptrend Bullish 3.74%
Jul 18 Upper Bollinger Band Walk Strength 3.74%
Jul 18 Multiple of Ten Bearish Other 3.74%
Jul 18 Outside Day Range Expansion 3.74%
Jul 18 Above Upper BB Strength 3.74%

Older signals for AKCA ...

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile
Akcea Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing drugs to treat patients with serious cardiometabolic diseases caused by lipid disorders. The Company's drugs, volanesorsen, AKCEA-APO(a)-LRx, AKCEA-ANGPTL3-LRx and AKCEA-APOCIII-LRx, are all based on antisense technology developed by Ionis Pharmaceuticals, Inc. (Ionis). The Company's volanesorsen drug has completed a Phase III clinical program for the treatment of familial chylomicronemia syndrome (FCS) and is currently in Phase III clinical development for the treatment of familial partial lipodystrophy (FPL). The Company's clinical pipeline contains drugs with the potential to treat inadequately addressed lipid disorders beyond elevated LDL-C that are contributing to the dramatic increase in the incidence of cardiometabolic disease, such as elevated triglycerides, oxidized phospholipids and other lipoproteins, such as lipoprotein(a), or Lp(a).
Is AKCA a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 4 bullish, 0 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 33.98
52 Week Low 12.25
Average Volume 311,719
200-Day Moving Average 21.9919
50-Day Moving Average 24.3548
20-Day Moving Average 26.1305
10-Day Moving Average 27.098
Average True Range 1.7146
ADX 28.02
+DI 28.4685
-DI 9.0046
Chandelier Exit (Long, 3 ATRs ) 25.3062
Chandelier Exit (Short, 3 ATRs ) 28.6738
Upper Bollinger Band 29.6861
Lower Bollinger Band 22.5749
Percent B (%b) 1.08
BandWidth 27.214175
MACD Line 1.2577
MACD Signal Line 0.7963
MACD Histogram 0.4614
Fundamentals Value
Market Cap 1.93 Billion
Num Shares 63.9 Million
EPS -1.89
Price-to-Earnings (P/E) Ratio -16.01
Price-to-Sales 0.00
Price-to-Book 0.00
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 33.37
Resistance 3 (R3) 33.09 31.77 32.85
Resistance 2 (R2) 31.77 30.98 31.91 32.68
Resistance 1 (R1) 31.01 30.48 31.39 31.29 32.50
Pivot Point 29.69 29.69 29.88 29.83 29.69
Support 1 (S1) 28.93 28.90 29.31 29.21 28.00
Support 2 (S2) 27.61 28.40 27.75 27.82
Support 3 (S3) 26.85 27.61 27.65
Support 4 (S4) 27.13